P13 Evaluation of <i>in vitro</i> activity of double β-lactam ‘therapy’ in ESBL+/CPE+ <i>Escherichia coli</i>—what is the association between ‘synergy’ and <i>in vitro</i> susceptibility?
JAC-antimicrobial resistance